Nuvalent, Inc.

Ownership Transactions Reported by 21 Insiders

Symbol
NUVL on Nasdaq
Industry
Pharmaceutical Preparations
Location
One Broadway, 14 Th Floor, Cambridge, MA

Insiders trading volume in the past year

Nuvalent, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
James E. Flynn Director, Director by Deputization, 10%+ Owner $1.2B Jun 18, 2025
Matthew Shair Director $159M -$6.7M -4.04% Oct 27, 2025
Andrew Hack Director $128M -$110M -46.3% Dec 11, 2024
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10%+ Owner $68.3M Aug 2, 2021
Deerfield Partners, L.P. Director, Director by Deputization, 10%+ Owner $49.5M Nov 3, 2022
James Richard Porter President and CEO, Director $23.1M -$24.6M -51.6% Oct 16, 2025
Alexandra Balcom Chief Financial Officer $6.45M -$14.3M -68.9% Nov 17, 2025
Henry E. Pelish Chief Scientific Officer $5.94M -$4.57M -43.5% Oct 15, 2025
Deborah Ann Miller Chief Legal Officer $5.25M -$8.05M -60.5% Nov 17, 2025
Christopher Durant Turner Chief Medical Officer $5.04M -$320K -5.97% Jan 6, 2025
Darlene Noci Chief Development Officer $5.02M -$5.32M -51.4% Oct 30, 2025
Grant C. Bogle Director $390K Jun 18, 2025
Anna Protopapas Director $343K Jun 18, 2025
Cameron Wheeler Director $343K Jun 18, 2025
Michael L. Meyers Director $343K Jun 18, 2025
Joseph Pearlberg Director $343K Jun 18, 2025
Sapna Srivastava Director $343K Jun 18, 2025
Christy J. Oliger Director $265K Jun 18, 2025
Emily Conley Director $213K Aug 23, 2024
Dwight Gary Gilliland Director $206K Jun 12, 2024
Robert Bowers Jackson Director Jul 28, 2021

Recent Insider Transactions by Companies or Individuals for Nuvalent, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.